LIGAND PHARMACEUTICALS INCORPORATED (LGND)

LGN (NASDAQ:LGN – Get Free Report) is one of 190 public companies in the “Construction & Engineering” industry, but how does it contrast to its rivals? We will compare LGN to similar businesses based on the strength of its dividends, valuation, risk, profitability, earnings, analyst ...

LGND stock opened at $296.29 on Friday. The firm’s fifty day simple moving average is $278.38 and its 200-day simple moving average is $231.36. The company has a market capitalization of $5.94 billion, a P/E ratio of 40.20, a price-to-earnings-growth ratio of 2.85 and a beta of 1.10.

London Stock Exchange Group (LON:LSEG - Get Free Report) released its quarterly earnings data on Thursday. The company reported GBX 244.90 EPS for the quarter. London Stock Exchange Group had a net margin of 13.41% and a return on equity of 6.10%.

London Stock Exchange Group's EBITDA margin reached 52.7% and was 90 basis points higher than Wall Street consensus. Learn why LDNXF stock is a buy.

Ligand Pharmaceuticals (NASDAQ:LGND) will be releasing its Q2 2026 earnings before the market opens on Thursday, August 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-8-6-ligand-pharmaceuticals-incorporated-stock/)